BioTuesdays

Category - Markets

BTIG cuts Valeritas Holdings to neutral; removes PT

BTIG downgraded Valeritas Holdings (NASDAQ:VLRX) to “neutral” from “buy” and removed its previous $10 price target after the company reduced its fourth quarter revenue guidance due to a temporary supply disruption and...

Roth starts Oxurion at buy; PT €9

Roth Capital Partners initiated coverage of Oxurion (Euronext Brussels:OXUR) with a “buy” rating and price target of €9. The stock was recently quoted at €2.41. “Our investment thesis is based on our understanding...

Ocugen

HCW starts Ocugen at buy; PT $1.25

H.C. Wainwright launched coverage of Ocugen (NASDAQ:OCGN) with a “buy” rating and price target of $1.25. The stock closed at 36 cents on Dec. 19. Ocugen is developing therapies for rare and underserved eye diseases and...

mesoblast

Dawson James starts Mesoblast at buy; PT $14

Dawson James Securities initiated coverage of Mesoblast (NASDAQ:MESO; ASX:MSB) with a “buy” rating and $14 price target. The stock closed at $7.42 on Dec. 18. Mesoblast is using its proprietary technology platform to...

X4 Pharma

Roth starts X4 Pharma at buy; PT $20

Roth Capital Partners launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $20 price target. The stock closed at $11 on Dec. 17. Analyst Zegbeh Jallah writes that her investment thesis is based...

Analysts downgrade and lower PTs for Aduro Biotech

William Blair downgraded Aduro Biotech (NASDAQ:ADRO) to “market perform” from “outperform” and H.C. Wainwright cut its price target for Aduro after Novartis removed Aduro’s intratumoral STING agonist, ADU-S100, from its...

Diffusion Pharma

HCW cuts Diffusion Pharma PT to $3.50 on dilution

H.C. Wainwright lowered its price target for Diffusion Pharmaceuticals (NASDAQ:DFFN) to $3.50 from $10, reflecting dilution from two recent financings. The stock closed at 41 cents on Dec. 17. Analyst Swayampakula...

Adamas Pharmaceuticals

SVB Leerink halves Adamas Pharma PT to $6

SVB Leerink lowered its price target for Adamas Pharmaceuticals (NASDAQ:ADMS) to $6 from $13, saying the mixed Phase 3 INROADS data are not good enough. In afternoon trading on Dec. 17, the stock was quoted at $4.15...

Wave Life Sciences

SVB Leerink ups Wave Life Sciences PT to $46 from $40

SVB Leerink raised its price target for Wave Life Sciences (NASDAQ:WVE) to $46 from $40 after the FDA approved Sarepta Therapeutics’ (NASDAQ:SRPT) golodirsen for the treatment of Duchenne muscular dystrophy (DMD) in...

Subscribe

Sign up to our weekly BioTuesdays newsletter.